The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.

Barbara L MeloskyParneet CheemaRosalyn A JuergensNatasha B LeighlGeoffrey LiuPaul Wheatley-PriceAdrian SacherStephanie SnowMing-Sound TsaoDeanna McLeodQuincy Siu-Chung Chu

Published in: Therapeutic advances in medical oncology (2021)

Adjuvant osimertinib used alone or following platinum-based chemotherapy is now recommended in patients with stage II-IIIA EGFR-mutated NSCLC.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
early stage
advanced non small cell lung cancer
brain metastases
tyrosine kinase
lymph node
locally advanced
prognostic factors